Lioresal

Lioresal is a brand name of baclofen, approved by the FDA in the following formulation(s):

LIORESAL (baclofen - injectable; intrathecal)

• 
  Manufacturer: MEDTRONIC
  
  Approval date: June 17, 1992
  
  Strength(s): 0.5MG/ML ^[RLD][AP], 2MG/ML ^[RLD][AP]


• 
  Manufacturer: MEDTRONIC
  
  Approval date: November 7, 1996
  
  Strength(s): 0.05MG/ML ^[RLD][AP]

Has a generic version of Lioresal been approved?

Yes. The following products are equivalent to Lioresal:

GABLOFEN (baclofen injectable; intrathecal)

• 
  Manufacturer: CNS THERAPS INC
  
  Approval date: November 19, 2010
  
  Strength(s): 0.05MG/ML ^[AP], 0.5MG/ML ^[AP], 2MG/ML ^[AP]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Lioresal. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

There are no current U.S. patents associated with Lioresal.

See also...

• Lioresal Consumer Information (Wolters Kluwer)
• Lioresal Consumer Information (Cerner Multum)
• Lioresal Advanced Consumer Information (Micromedex)
• Lioresal Double Strength Advanced Consumer Information (Micromedex)
• Lioresal Intrathecal Advanced Consumer Information (Micromedex)
• Lioresal AHFS DI Monographs (ASHP)
• Baclofen Consumer Information (Drugs.com)
• Baclofen Consumer Information (Wolters Kluwer)
• Baclofen Tablets Consumer Information (Wolters Kluwer)
• Baclofen Consumer Information (Cerner Multum)
• Baclofen Advanced Consumer Information (Micromedex)
• Baclofen Intrathecal Advanced Consumer Information (Micromedex)
• Baclofen AHFS DI Monographs (ASHP)

Skelaxin

Skelaxin is a brand name of metaxalone, approved by the FDA in the following formulation(s):

SKELAXIN (metaxalone - tablet; oral)

• 
  Manufacturer: KING PHARMS
  
  Approval date: August 30, 2002
  
  Strength(s): 800MG ^[RLD][AB]

Has a generic version of Skelaxin been approved?

A generic version of Skelaxin has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Skelaxin and have been approved by the FDA:

metaxalone tablet; oral

• 
  Manufacturer: SANDOZ
  
  Approval date: March 31, 2010
  
  Strength(s): 800MG ^[AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Skelaxin. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Method for increasing the bioavailability of metaxalone
  Patent 6,407,128
  Issued: June 18, 2002
  Inventor(s): Michael; Scaife & Jaymin; Shah
  Assignee(s): Elan Pharmaceuticals, Inc.
  A method of increasing the bioavailability of metaxalone by administration of an oral dosage form with food is provided, as well as an article of manufacture comprising an oral dosage form of metaxalone in a suitable container and associated with printed labeling which describes the increased bioavailability of the medication in the container when taken with food.
  
  Patent expiration dates:
  
  
  • December 3, 2021
    
    ✓ 
    Patent use: ENHANCEMENT OF THE BIOAVAILABILITY OF THE DRUG SUBSTANCE
  
  



• 
  Methods of using metaxalone in the treatment of musculoskeletal conditions
  Patent 6,683,102
  Issued: January 27, 2004
  Inventor(s): Michael; Scaife & Jaymin; Shah
  Assignee(s): Elan Pharmaceuticals, Inc.
  A method of increasing the bioavailability of metaxalone by administration of an oral dosage form with food is provided, as well as an article of manufacture comprising an oral dosage form of metaxalone in a suitable container and associated with printed labeling which describes the increased bioavailability of the medication in the container when taken with food.
  
  Patent expiration dates:
  
  
  • December 3, 2021
    
    ✓ 
    Patent use: ENHANCEMENT OF THE BIOAVAILABILITY OF THE DRUG SUBSTANCE
  
  



• 
  Metaxalone products, method of manufacture, and method of use
  Patent 7,122,566
  Issued: October 17, 2006
  Inventor(s): Du; Jie & Roberts; Richard H.
  Assignee(s): Mutual Pharmaceutical Company, Inc.
  Disclosed herein is a method of using metaxalone. In one embodiment, the method comprises obtaining metaxalone from a container providing information that metaxalone affects the activity of a cytochrome p450 isozyme. In another embodiment, the method comprises informing a user that metaxalone affects the activity of a cytochrome p450 isozyme. Also included are articles of manufacture comprising a container containing a dosage form of metaxalone, wherein the container is associated with published material informing that metaxalone affects activity of a cytochrome p450 isozyme. Also disclosed are a method of treatment and a method of manufacturing a metaxalone product.
  
  Patent expiration dates:
  
  
  • February 6, 2026
    
    ✓ 
    Patent use: TREATMENT OF MUSCULOSKELETAL CONDITIONS
  
  



• 
  Methods of modifying the bioavailability of metaxalone
  Patent 7,714,006
  Issued: May 11, 2010
  Inventor(s): Scaife; Michael C. & Davis; Charles C.
  Assignee(s): King Pharmaceuticals Research & Development, Inc.
  A method of increasing the bioavailability, and decreasing the effect of age on the bioavailability, of metaxalone, by administration of an oral dosage form with food is provided, as well as an article of manufacture comprising an oral dosage form of metaxalone in a suitable container and associated with printed labeling which describes the increased bioavailability, and decreased effect of age on bioavailability, of the medication in the container, when taken with food.
  
  Patent expiration dates:
  
  
  • December 3, 2021
    
    ✓ 
    Patent use: USE OF METAXALONE FOR TREATMENT OF MUSCULSKELETAL CONDITIONS
  
  

See also...

• Skelaxin Consumer Information (Drugs.com)
• Skelaxin Consumer Information (Wolters Kluwer)
• Skelaxin Consumer Information (Cerner Multum)
• Skelaxin Advanced Consumer Information (Micromedex)
• Skelaxin AHFS DI Monographs (ASHP)
• Metaxalone Consumer Information (Wolters Kluwer)
• Metaxalone Consumer Information (Cerner Multum)
• Metaxalone Advanced Consumer Information (Micromedex)
• Metaxalone AHFS DI Monographs (ASHP)

Simcor

Simcor is a brand name of niacin/simvastatin, approved by the FDA in the following formulation(s):

SIMCOR (niacin; simvastatin - tablet, extended release; oral)

• 
  Manufacturer: ABBOTT
  
  Approval date: February 15, 2008
  
  Strength(s): 1GM;20MG ^[RLD], 500MG;20MG ^[RLD], 750MG;20MG ^[RLD]


• 
  Manufacturer: ABBOTT
  
  Approval date: July 28, 2010
  
  Strength(s): 1GM;40MG ^[RLD], 500MG;40MG ^[RLD]

Has a generic version of Simcor been approved?

No. There is currently no therapeutically equivalent version of Simcor available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Simcor. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Nicotinic acid compositions for treating hyperlipidemia and related methods therefor
  Patent 6,080,428
  Issued: June 27, 2000
  Inventor(s): Bova; David J.
  An orally administered antihyperlipidemia composition according to the present invention includes from about 250 to about 3000 parts by weight of nicotinic acid, and from about 5 to about 50 parts by weight of hydroxypropyl methylcellulose. Also, a method of treating hyperlipidemia in a hyperlipidemic having a substantially periodic physiological loss of consciousness, includes the steps of forming a composition having an effective antihyperlipidemic amount of nicotinic acid and a time release sustaining amount of a swelling agent. The method also includes the step of orally administering the composition to the hyperlipidemic once per day "nocturnally", that is in the evening or at night.
  
  Patent expiration dates:
  
  
  • May 27, 2017
    
    ✓ 
    Patent use: TREATMENT OF HYPERCHOLESTEROLEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT
  
  
  
  • May 27, 2017
    
    ✓ 
    Patent use: TREATMENT OF HYPERTRIGLYCERIDEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT
  
  
  
  • May 27, 2017
    
    ✓ 
    Patent use: ADJUNCT TO DIET TO REDUCE ELEVATED TOTAL-C, LDL-C, NON-HDL-C, APO B, TG, AND LP(A) LEVELS AND TO INCREASE HDL-C IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA, MIXED DYSLIPIDEMIA, AND HYPERTRIGLYCERIDEMIA
  
  



• 
  Methods and sustained release nicotinic acid compositions for treating hyperlipidemia at night
  Patent 6,129,930
  Issued: October 10, 2000
  Inventor(s): Bova; David J.
  An orally administered antihyperlipidemia composition according to the present invention includes from about 250 to about 3000 parts by weight of nicotinic acid, and from about 5 to about 50 parts by weight of hydroxypropyl methylcellulose. Also, a method of treating hyperlipidemia in a hyperlipidemic having a substantially periodic physiological loss of consciousness, includes the steps of forming a composition having an effective antihyperlipidemic amount of nicotinic acid and a time release sustaining amount of a swelling agent. The method also includes the step of orally administering the composition to the hyperlipidemic once per day "nocturnally," that is in the evening or at night.
  
  Patent expiration dates:
  
  
  • September 20, 2013
    
    ✓ 
    Patent use: ADJUNCT TO DIET TO REDUCE ELEVATED TOTAL-C, LDL-C, NON-HDL-C, APO B, TG, AND LP(A) LEVELS AND TO INCREASE HDL-C IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA, MIXED DYSLIPIDEMIA, AND HYPERTRIGLYCERIDEMIA
    ✓ 
    Drug product
  
  
  
  • September 20, 2013
    
    ✓ 
    Patent use: TREATMENT OF HYPERTRIGLYCERIDEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT
    ✓ 
    Drug product
  
  
  
  • September 20, 2013
    
    ✓ 
    Patent use: TREATMENT OF HYPERCHOLESTEROLEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT
    ✓ 
    Drug product
  
  



• 
  Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique urinary metabolite profiles
  Patent 6,406,715
  Issued: June 18, 2002
  Inventor(s): Eugenio A.; Cefali
  Assignee(s): Kos Pharmaceuticals, Inc.
  Intermediate release nicotinic acid formulations having unique urinary metabolite profiles, which are suitable for oral administration once-a-day as a single dose during a 24 hour period for treating hyperlipidemia without causing drug-induced hepatotoxicity or drug-induced elevations in uric acid or glucose or both to levels that require the therapy to be discontinued, are disclosed.
  
  Patent expiration dates:
  
  
  • September 20, 2013
    
    ✓ 
    Drug product
  
  



• 
  Methods of pretreating hyperlipidemic individuals with a flush inhibiting agent prior to the start of single daily dose nicotinic acid therapy to reduce flushing provoked by nicotinic acid
  Patent 6,469,035
  Issued: October 22, 2002
  Inventor(s): Eugenio A.; Cefali
  The present invention relates to pretreating individuals with an effective amount of a flush inhibiting agent for a sufficient period of time prior to the start of single daily dose nicotinic acid therapy to reduce the capacity of nicotinic acid to induce flushing reactions in such individuals during nicotinic acid therapy. In accordance with the present invention, the flush inhibiting agents are administered orally one to four times a day, and preferably one to two times per day, for between about 7 to about 14 days prior to the start of the nicotinic acid therapy. Examples of flush inhibiting agents include nonsteroidal anti-inflammatory agents. Aspirin is a preferred flush inhibiting agent and may be orally administered in daily doses of between about 80 mg to about 1000 mg, and preferably between about 80 mg and about 650 mg, and more preferably between about 80 mg and about 325 mg, during the pretreatment period. Also consistent with the present invention, the pretreatment therapy may be continued during and administered concurrently with the nicotinic acid therapy, in which the nicotinic acid is preferably administered once per day as a single dose during the evening hours or before or at bedtime. The nicotinic acid may be administered alone or in combination with HMG-CoA reductase inhibitors as well as other lipid-altering agents, like cholestyramine and colestipol.
  
  Patent expiration dates:
  
  
  • March 15, 2018
    
    ✓ 
    Patent use: TAKING ASPIRIN OR NON-STEROIDAL ANTI-INFLAMMATORY MEDICATIONS APPROXIMATELY 30 MINUTES BEFORE DOSING CAN MINIMIZE FLUSHING, A COMMON SIDE EFFECT OF NIACIN THERAPY
  
  
  
  • March 15, 2018
    
    ✓ 
    Patent use: TREATMENT OF HYPERTRIGLYCERIDEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, WITH PRETREATMENT WITH A FLUSH INHIBITING AGENT SUCH AS ASPIRIN
  
  
  
  • March 15, 2018
    
    ✓ 
    Patent use: TREATMENT OF HYPERCHOLESTEROLEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, WITH PRETREATMENT WITH A FLUSH INHIBITIN AGENT SUCH AS ASPIRIN
  
  



• 
  Methods for reducing flushing in individuals being treated with nicotinic acid for hyperlipidemia
  Patent 6,676,967
  Issued: January 13, 2004
  Inventor(s): Eugenio A.; Cefali & David J.; Bova
  Assignee(s): KOS Pharmaceuticals, Inc.
  Methods for reducing flushing in individuals being treated for hyperlipidemia with nicotinic acid are disclosed. According to the methods of the present invention, flushing can be reduced in individuals under going nicotinic acid therapy without causing drug-induced hepatotoxicity to a level that would require the nicotinic acid therapy to be discontinued by orally administering to the individuals intermediate nicotinic acid formualtions having unique biopharmaceutical characteristics as a single dose once per day. While the methods of the present invention contemplate administering the intermediate release nicotinic acid formulations at any time during a 24 hour period, it is preferable to administer them once-a-day as a single dose during the evening or at night between about 6:00 pm. and 12:00 a.m., preferably between about 8:00 p.m. and 12:00 a.m., and most preferably between about 8:00 p.m. and 10:00 p.m.
  
  Patent expiration dates:
  
  
  • September 20, 2013
    
    ✓ 
    Patent use: TREATMENT OF HYPERTRIGLYCERIDEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT
  
  
  
  • September 20, 2013
    
    ✓ 
    Patent use: ADJUNCT TO DIET TO REDUCE ELEVATED TOTAL-C, LDL-C, NON-HDL-C, APO B, TG, AND LP(A) LEVELS AND TO INCREASE HDL-C IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA, MIXED DYSLIPIDEMIA, AND HYPERTRIGLYCERIDEMIA
  
  
  
  • September 20, 2013
    
    ✓ 
    Patent use: TREATMENT OF HYPERCHOLESTEROLEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT
  
  



• 
  Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique biopharmaceutical characteristics
  Patent 6,746,691
  Issued: June 8, 2004
  Inventor(s): Eugenio A.; Cefali
  Assignee(s): Kos Pharmaceuticals, Inc.
  Intermediate release nicotinic acid formulations having unique biopharmaceutical characteristics, which are suitable for oral administration once per day as a single dose preferably administered during the evening or at night for treating hyperlipidemia without causing drug-induced hepatotoxicity to such a level that requires the therapy to be discontinued, are disclosed. The intermediate nicotinic acid formulations can be administered as tablets in dosage strengths of, for example, 375 mg, 500 mg, 750 mg and 1000 mg. The 375 mg, 500 mg and 750 mg nicotinic acid tablets of the present invention have a dissolution curve similarity fit factor F2 of at least about 79, and the 1000 mg nicotinic acid tablets of the present invention have a dissolution curve similarity fit factor F2 of at least 44.
  
  Patent expiration dates:
  
  
  • September 20, 2013
    
    ✓ 
    Drug product
  
  



• 
  Intermediate release nicotinic acid compositions for treating hyperlipidemia
  Patent 6,818,229
  Issued: November 16, 2004
  Inventor(s): Eugenio A.; Cefali & David J.; Bova
  Assignee(s): KOS Pharmaceuticals, Inc.
  Intermediate release nicotinic acid formulations having unique biopharmaceutical characteristics, such as Cmax, Tmax and AUC, which are suitable for oral administration once per day during the evening or at night for treating hyperlipidemia without causing drug-induced hepatotoxicity to such a level that requires the therapy to be discontinued, are disclosed. The intermediate nicotinic acid formulations can be administered as tablets in dosage strengths of, for example, 375 mg, 500 mg, 750 mg and 1000 mg.
  
  Patent expiration dates:
  
  
  • September 20, 2013
    
    ✓ 
    Drug product
  
  



• 
  Hydrophobic component free sustained release nicotinic acid compositions for treating hyperlipidemia and related methods therefor
  Patent 7,011,848
  Issued: March 14, 2006
  Inventor(s): Bova; David J.
  Assignee(s): KOS Pharmaceuticals, Inc.
  An orally administered antihyperlipidemia composition according to the present invention includes from about 250 to about 3000 parts by weight of nicotinic acid, and from about 5 to about 50 parts by weight of hydroxypropyl methylcellulose. Also, a method of treating hyperlipidemia in a hyperlipidemic having a substantially periodic physiological loss of consciousness, includes the steps of forming a composition having an effective antihyperlipidemic amount of nicotinic acid and a time release sustaining amount of a swelling agent. The method also includes the step of orally administering the composition to the hyperlipidemic once per day “nocturnally,” that is in the evening or at night.
  
  Patent expiration dates:
  
  
  • September 20, 2013
    
    ✓ 
    Patent use: ADJUNCT TO DIET TO REDUCE ELEVATED TOTAL-C, LDL-C, NON-HDL-C, APO B, TG, AND LP(A) LEVELS AND TO INCREASE HDL-C IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA, MIXED DYSLIPIDEMIA, AND HYPERTRIGLYCERIDEMIA
  
  
  
  • September 20, 2013
    
    ✓ 
    Patent use: TREATMENT OF HYPERTRIGLYCDERIDEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, THROUGH REDUCTION IN TOTAL-C, LDL-C, LP(A), AND INCREASE OF HDL-C
  
  
  
  • September 20, 2013
    
    ✓ 
    Patent use: TRETMENT OF HYPERCHOLESTEROLEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, THROUGH REDUCTION IN TOTAL-C, LDL-C, TG, LP(A), AND INCREASE OF HDL-C
  
  



• 
  Nicotinic acid compositions for treating hyperlipidemia and related methods therefor
  Patent 7,998,506
  Issued: August 16, 2011
  Inventor(s): Bova; David J
  Assignee(s): KOS Life Sciences, Inc.
  An orally administered antihyperlipidemia composition according to the present invention includes from about 250 to about 3000 parts by weight of nicotinic acid, and from about 5 to about 50 parts by weight of hydroxypropyl methylcellulose. Also, a method of treating hyperlipidemia in a hyperlipidemic having a substantially periodic physiological loss of consciousness, includes the steps of forming a composition having an effective antihyperlipidemic amount of nicotinic acid and a time release sustaining amount of a swelling agent. The method also includes the step of orally administering the composition to the hyperlipidemic once per day “nocturnally,” that is in the evening or at night.
  
  Patent expiration dates:
  
  
  • September 20, 2013
    
    ✓ 
    Patent use: TRETMENT OF HYPERCHOLESTEROLEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, THROUGH REDUCTION IN TOTAL-C, LDL-C, TG, LP(A), AND INCREASE OF HDL-C
  
  
  
  • September 20, 2013
    
    ✓ 
    Patent use: TREATMENT OF HYPERTRIGLYCDERIDEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, THROUGH REDUCTION IN TOTAL-C, LDL-C, LP(A), AND INCREASE OF HDL-C
  
  

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • February 15, 2011 - NEW COMBINATION
  
  

See also...

• Simcor Consumer Information (Drugs.com)
• Simcor Consumer Information (Wolters Kluwer)
• Simcor Consumer Information (Cerner Multum)
• Simcor Advanced Consumer Information (Micromedex)
• Simvastatin/Niacin Consumer Information (Wolters Kluwer)
• Niacin and simvastatin Consumer Information (Cerner Multum)
• Simvastatin and niacin Advanced Consumer Information (Micromedex)

Elocon

Elocon is a brand name of mometasone topical, approved by the FDA in the following formulation(s):

ELOCON (mometasone furoate - cream; topical)

• 
  Manufacturer: SCHERING
  
  Approval date: May 6, 1987
  
  Strength(s): 0.1% ^[RLD][AB]

ELOCON (mometasone furoate - lotion; topical)

• 
  Manufacturer: SCHERING
  
  Approval date: March 30, 1989
  
  Strength(s): 0.1% ^[RLD][AB]

ELOCON (mometasone furoate - ointment; topical)

• 
  Manufacturer: SCHERING
  
  Approval date: April 30, 1987
  
  Strength(s): 0.1% ^[RLD][AB]

Has a generic version of Elocon been approved?

Yes. The following products are equivalent to Elocon:

mometasone furoate cream; topical

• 
  Manufacturer: FOUGERA PHARMS
  
  Approval date: April 8, 2005
  
  Strength(s): 0.1% ^[AB]


• 
  Manufacturer: G AND W LABS
  
  Approval date: May 22, 2006
  
  Strength(s): 0.1% ^[AB]


• 
  Manufacturer: GLENMARK GENERICS
  
  Approval date: May 28, 2008
  
  Strength(s): 0.1% ^[AB]


• 
  Manufacturer: TARO
  
  Approval date: December 21, 2004
  
  Strength(s): 0.1% ^[AB]


• 
  Manufacturer: TOLMAR
  
  Approval date: April 18, 2007
  
  Strength(s): 0.1% ^[AB]

mometasone furoate lotion; topical

• 
  Manufacturer: FOUGERA PHARMS
  
  Approval date: November 29, 2007
  
  Strength(s): 0.1% ^[AB]


• 
  Manufacturer: G AND W LABS
  
  Approval date: November 21, 2007
  
  Strength(s): 0.1% ^[AB]


• 
  Manufacturer: GLENMARK GENERICS
  
  Approval date: August 9, 2010
  
  Strength(s): 0.1% ^[AB]


• 
  Manufacturer: PERRIGO
  
  Approval date: April 6, 2005
  
  Strength(s): 0.1% ^[AB]


• 
  Manufacturer: TARO
  
  Approval date: March 15, 2006
  
  Strength(s): 0.1% ^[AB]


• 
  Manufacturer: TOLMAR
  
  Approval date: November 21, 2007
  
  Strength(s): 0.1% ^[AB]

mometasone furoate ointment; topical

• 
  Manufacturer: FOUGERA PHARMS
  
  Approval date: March 28, 2005
  
  Strength(s): 0.1% ^[AB]


• 
  Manufacturer: G AND W LABS
  
  Approval date: June 20, 2006
  
  Strength(s): 0.1% ^[AB]


• 
  Manufacturer: GLENMARK GENERICS
  
  Approval date: May 28, 2008
  
  Strength(s): 0.1% ^[AB]


• 
  Manufacturer: PERRIGO NEW YORK
  
  Approval date: March 18, 2002
  
  Strength(s): 0.1% ^[AB]


• 
  Manufacturer: TARO
  
  Approval date: December 3, 2004
  
  Strength(s): 0.1% ^[AB]


• 
  Manufacturer: TOLMAR
  
  Approval date: November 14, 2003
  
  Strength(s): 0.1% ^[AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Elocon. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

There are no current U.S. patents associated with Elocon.

See also...

• Elocon Consumer Information (Drugs.com)
• Elocon Cream Consumer Information (Wolters Kluwer)
• Elocon Lotion Consumer Information (Wolters Kluwer)
• Elocon Consumer Information (Cerner Multum)
• Elocon Advanced Consumer Information (Micromedex)
• Elocon topical AHFS DI Monographs (ASHP)
• Mometasone Cream Consumer Information (Wolters Kluwer)
• Mometasone Lotion Consumer Information (Wolters Kluwer)
• Mometasone topical Consumer Information (Cerner Multum)
• Elocom Advanced Consumer Information (Micromedex)
• Pms-Mometasone Advanced Consumer Information (Micromedex)
• Mometasone Topical application Advanced Consumer Information (Micromedex)
• Mometasone Furoate topical AHFS DI Monographs (ASHP)

Lotronex

Lotronex is a brand name of alosetron, approved by the FDA in the following formulation(s):

LOTRONEX (alosetron hydrochloride - tablet; oral)

• 
  Manufacturer: PROMETHEUS LABS
  
  Approval date: February 9, 2000
  
  Strength(s): EQ 1MG BASE ^[RLD]


• 
  Manufacturer: PROMETHEUS LABS
  
  Approval date: December 23, 2003
  
  Strength(s): EQ 0.5MG BASE
  

Has a generic version of Lotronex been approved?

No. There is currently no therapeutically equivalent version of Lotronex available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Lotronex. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Tetrahydro-1H-pyrido[4,3-b]indol-1-one derivatives
  Patent 5,360,800
  Issued: November 1, 1994
  Inventor(s): Coates; Ian H. & North; Peter C. & Oxford; Alexander W.
  Assignee(s): Glaxo Group Limited
  The invention relates to tricyclic lactams of the general formula (I) ##STR1## wherein Im represents an imidazolyl group of the formula: ##STR2## and R.sup.1 represents a hydrogen atom or a group selected from C.sub.1-6 alkyl, C.sub.3-6 alkenyl, C.sub.3-10 alkynyl, C.sub.3-7 cycloalkyl, C.sub.3-7 cycloalkylC.sub.1-4 alkyl, phenyl, phenyl C.sub.1-3 alkyl, phenylmethoxymethyl, phenoxyethyl or phenoxymethyl, one of the groups represented by R.sup.2, R.sup.3 and R.sup.4 is a hydrogen atom or a C.sub.1-6 alkyl, C.sub.3-7 cycloalkyl, C.sub.3-6 alkenyl, phenyl or phenyl C.sub.1-3 alkyl group, and each of the other two groups, which may be the same or different, represents a hydrogen atom or a C.sub.1-6 alkhyl group; n represents 2 or 3; and physiologically acceptable salts and solvates thereof. The compounds are potent and selective antagonists of the effect of 5-HT at 5-HT.sub.3 receptors and are useful, for example, in the treatment of psychotic disorders, anxiety, and nausea and vomiting.
  
  Patent expiration dates:
  
  
  • January 13, 2013
    
    ✓ 
    Patent use: FOR WOMEN WITH SEVERE DIARRHEA-PREDOMINANT IRRITABLE BOWEL SYNDROME (IBS)
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  



• 
  Medicaments for the treatment of non-constipated female irritable bowel syndrome
  Patent 6,284,770
  Issued: September 4, 2001
  Inventor(s): Mangel; Allen Wayne & Northcutt; Allison Ruth
  Assignee(s): Glaxo Wellcome Inc.
  This invention relates to the use of 5-HT3 receptor antagonists in the treatment of nonconstipated female IBS patients.
  
  Patent expiration dates:
  
  
  • October 5, 2018
    
    ✓ 
    Patent use: FOR WOMEN WITH SEVERE DIARRHEA-PREDOMINANT IRRITABLE BOWEL SYNDROME (IBS)
  
  

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • April 1, 2011 - ONCE DAILY DOSING REGIMEN FOR PATIENTS WHO BECOME CONSTIPATED ON TWICE DAILY REGIMEN
  
  

See also...

• Lotronex Consumer Information (Drugs.com)
• Lotronex Consumer Information (Wolters Kluwer)
• Lotronex Consumer Information (Cerner Multum)
• Lotronex Advanced Consumer Information (Micromedex)
• Lotronex AHFS DI Monographs (ASHP)
• Alosetron Consumer Information (Wolters Kluwer)
• Alosetron Consumer Information (Cerner Multum)
• Alosetron Advanced Consumer Information (Micromedex)
• Alosetron Hydrochloride AHFS DI Monographs (ASHP)

Gulf War Syndrome Medications

There are currently no drugs listed for "Gulf War Syndrome". See Organophosphate Poisoning.

Definition of Gulf War Syndrome:

Gulf War Syndrome is a cluster of health problems experienced by U.S. military personnel after serving in the Persian Gulf conflict of 1991; includes fatigue, musculoskeletal pain, headaches, dyspnea, memory loss, and diarrhea; thought to be related to exposure to low levels of neurotoxins, including sarin, pesticides, and pyridostigmine bromide (the latter supplied to troops as a protective anti-toxin).

Drug List:

Gitelman Syndrome Medications

Drugs associated with Gitelman Syndrome

The following drugs and medications are in some way related to, or used in the treatment of Gitelman Syndrome. This service should be used as a supplement to, and NOT a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

Drug List:

Indocin

Indocin-Iv

Indocin-Sr-Sustained-Release-Capsules